Similar Search Results

Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)

Zettl, Uwe; Henze, Thomas; Essner, Ute; Flachenecker, Peter - In: The European Journal of Health Economics 15 (2014) 9, pp. 953-966

MS patients with spasticity suffer a significant burden because of resulting disabilities and reduced QoL, especially in cases of severe spasticity. Moreover, spasticity causes high costs that increase with increasing severity. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2014

Persistent link: https://www.econbiz.de/10011151202

The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom

Bonastre, J.; Pen, C. Le; Anderson, P.; Ganz, A.; Berto, P. - In: The European Journal of Health Economics 3 (2002) 2, pp. 94-102

% of persons with CNV can benefit from it. Photodynamic therapy (PDT), a new treatment for CNV, reduces the risk of vision …

Persistent link: https://www.econbiz.de/10010845770

Cost of care for colorectal cancer in Ireland: a health care payer perspective

Tilson, L.; Sharp, L.; Usher, C.; Walsh, C.; S, Whyte; … - In: The European Journal of Health Economics 13 (2012) 4, pp. 511-524

Persistent link: https://www.econbiz.de/10010845781

Modelling the costs and effects of leflunomide in rheumatoid arthritis

Kobelt, G.; Lindgren, P.; Young, A. - In: The European Journal of Health Economics 3 (2002) 3, pp. 180-187

This study investigated the cost-effectiveness of leflunomide (LEF) compared to methotrexate (MTX) and sulfasalazine … was reversed (£34,070 and 4.487 QALYs for MTX compared to £36,351 and 4.372 QALYs for LEF). Compared to SSZ, the cost of … the US trial may be more relevant for the UK. Compared to SSZ, the use of LEF appears to be cost-effective in the UK …

Persistent link: https://www.econbiz.de/10010993821

What can we learn from international comparisons of costs by DRG?

Pirson, M.; Schenker, L.; Martins, D.; Dung, Duong; … - In: The European Journal of Health Economics 14 (2013) 1, pp. 67-73

It is possible to make international comparisons but only if there is standardization of the case-mix between countries and only if comparable accountancy methodologies are used. Harmonization of DRGs groups, nomenclature and accountancy is thus required. </AbstractSection> Copyright Springer-Verlag 2013

Persistent link: https://www.econbiz.de/10010993842

Estimating the social cost of respiratory cancer cases attributable to occupational exposures in France

Serrier, Hassan; Sultan-Taieb, Hélène; Luce, Danièle; … - In: The European Journal of Health Economics 15 (2014) 6, pp. 661-673

Our assessment shows the magnitude of the economic impact of occupational respiratory cancers. It allows comparisons between countries and provides valuable information for policy-makers responsible for defining public health priorities. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2014

Persistent link: https://www.econbiz.de/10010993854

The cost of Type 1 diabetes mellitus in the United Kingdom: a review of cost-of-illness studies

Kruger, Jen; Brennan, Alan - In: The European Journal of Health Economics 14 (2013) 6, pp. 887-899

There is no recently published estimate of the cost of Type 1 DM in the UK; therefore, it is recommended that an up …-to-date national, comprehensive cost-of-illness study should be conducted. Recommendations for the format of this study are made …

Persistent link: https://www.econbiz.de/10010993895

Drug expenditure of high-cost patients and their characteristics in Finland

Saastamoinen, Leena; Verho, Jouko - In: The European Journal of Health Economics 14 (2013) 3, pp. 495-502

The skewness of the cost distribution indicates a need for more patient-specific cost-containment methods, and the high … number of drugs in the high-cost group calls for exploring the possibilities of disease management and patient monitoring … techniques in cost containment. </AbstractSection> Copyright Springer-Verlag 2013 …

Persistent link: https://www.econbiz.de/10010993914

Lifetime costs of the top five cancers in Taiwan

Lang, Hui-Chu; Wu, Shi-Liang - In: The European Journal of Health Economics 13 (2012) 3, pp. 347-353

Persistent link: https://www.econbiz.de/10010557840

Resource use and costs of treating acute cough/lower respiratory tract infections in 13 European countries: results and challenges

Oppong, Raymond; Coast, Joanna; Hood, Kerry; Nuttall, Jacqui - In: The European Journal of Health Economics 12 (2011) 4, pp. 319-329

Persistent link: https://www.econbiz.de/10009149804